Ipsen climbs 4%, making it one of the SBF120's biggest gainers, with the support of UBS, which has raised its recommendation from 'neutral' to 'buy' and its price target from 113 to 150 euros, on the pharmaceutical company's stock.

Seeing in Ipsen a 'superior growth profile but trading at a discount', the broker sees 'more room for revaluation as Ipsen continually demonstrates its ability to replenish its pipeline'.

Copyright (c) 2023 CercleFinance.com. All rights reserved.